Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Wroblewski

Brust-Sisti

Bridgeman

MB.

Vaccines for respiratory syncytial virus prevention in older adults. Ann Pharmacother. 2024;58(12):1218-1228. doi:10.1177/10600280241241049

US Food and Drug Administration. FDA roundup: May 31, 2024. Accessed July 23, 2024. https://www.fda.gov/news-events/press-announcements/fda-roundup-may-31-2024

Qiu

, et al Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022;68:37-53. doi:10.1016/j.cytogfr.2022.10.001

Hajiaghapour Asr

Dayani

Saedi Segherloo

, et al Lipid nanoparticles as promising carriers for mRNA vaccines for viral lung infections. Pharmaceutics. 2023;15(4):1127. doi:10.3390/pharmaceutics15041127

Wilson

Goswami

Baqui

, et al Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233-2244. doi:10.1056/NEJMoa2307079

Makhijani

Elossaily

Rojekar

Ingle

RG.

MRNA-based vaccines—global approach, challenges, and could be a promising wayout for future pandemics. Pharm Dev Technol. 2024;29(6):559-565. doi:10.1080/10837450.2024.2361656

FDA Approves mRESVIA: Embracing the New Era of RSV Prevention With Advanced mRNA Technology

Abstract

Get full access to this article

References